PortalPublikationenPeripheral blood cytogenetics allows treatment monitoring an...

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial

Standard

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. / Braulke, Friederike; Schulz, Xenia; Germing, Ulrich; Schuler, Esther; Platzbecker, Uwe; Nolte, Florian; Hofmann, Wolf-Karsten; Giagounidis, Aristoteles; Götze, Katharina; Lübbert, Michael; Schlenk, Richard F; Schanz, Julie; Bacher, Ulrike; Ganser, Arnold; Büsche, Guntram; Letsch, Anne; Schafhausen, Philippe; Bug, Gesine; Brümmendorf, Tim H; Haas, Rainer; Trümper, Lorenz; Shirneshan, Katayoon; Haase, Detlef.

in: ANN HEMATOL, Jahrgang 96, Nr. 6, 06.2017, S. 887-894.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Braulke, F, Schulz, X, Germing, U, Schuler, E, Platzbecker, U, Nolte, F, Hofmann, W-K, Giagounidis, A, Götze, K, Lübbert, M, Schlenk, RF, Schanz, J, Bacher, U, Ganser, A, Büsche, G, Letsch, A, Schafhausen, P, Bug, G, Brümmendorf, TH, Haas, R, Trümper, L, Shirneshan, K & Haase, D 2017, 'Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial', ANN HEMATOL, Jg. 96, Nr. 6, S. 887-894. https://doi.org/10.1007/s00277-017-2983-0

APA

Braulke, F., Schulz, X., Germing, U., Schuler, E., Platzbecker, U., Nolte, F., Hofmann, W-K., Giagounidis, A., Götze, K., Lübbert, M., Schlenk, R. F., Schanz, J., Bacher, U., Ganser, A., Büsche, G., Letsch, A., Schafhausen, P., Bug, G., Brümmendorf, T. H., ... Haase, D. (2017). Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. ANN HEMATOL, 96(6), 887-894. https://doi.org/10.1007/s00277-017-2983-0

Vancouver

Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F et al. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. ANN HEMATOL. 2017 Jun;96(6):887-894. https://doi.org/10.1007/s00277-017-2983-0

Bibtex

@article{efc27ebaed0047fda81f6b0c134cdbb6,
title = "Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial",
abstract = "Transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndrome, <5% bone marrow (BM) blasts and isolated 5q-deletion received lenalidomide within the German MDS study group phase-II clinical trial LE-MON-5 (EudraCT:2008-001866-10) of the University of Duesseldorf, Germany. Cytogenetic monitoring was performed by chromosome banding analyses (CBA) of BM cells and fluorescence in situ hybridization (FISH) analyses of peripheral blood (PB) mononuclear CD34+ cells using extended probe panels. Out of 144 patients screened for study enrollment, 24% failed to meet inclusion criteria due to cytogenetic findings. Eighty-seven patients were followed with a median observation time of 30 months. Cytogenetic response detected by FISH and CBA in 74 and 66% of patients, respectively, was predictive for hematologic response as well as of high prognostic relevance. After 2 years, AML rate was 8% for all patients. Karyotype evolution was detected in 21 (FISH)-34% (CBA) of patients associated with significantly shorter AML-free survival. Disease progression was first detectable on the cytogenetic level on average 5-6 months before recurrence of transfusion dependence. Our data show for the first time in a prospective setting that a cytogenetic monitoring from the PB helps to early identify treatment failure and progressive disease in lenalidomide-treated patients to improve clinical management.TRIAL REGISTRATION: EudraCT:2008-001866-10.",
keywords = "Acute Disease, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Antigens, CD34, Chromosome Banding, Chromosome Deletion, Chromosomes, Human, Pair 5, Disease-Free Survival, Female, Germany, Humans, In Situ Hybridization, Fluorescence, Karyotyping, Leukemia, Myeloid, Leukocytes, Mononuclear, Male, Middle Aged, Myelodysplastic Syndromes, Prognosis, Thalidomide, Treatment Failure, Clinical Trial, Phase II, Journal Article, Multicenter Study",
author = "Friederike Braulke and Xenia Schulz and Ulrich Germing and Esther Schuler and Uwe Platzbecker and Florian Nolte and Wolf-Karsten Hofmann and Aristoteles Giagounidis and Katharina G{\"o}tze and Michael L{\"u}bbert and Schlenk, {Richard F} and Julie Schanz and Ulrike Bacher and Arnold Ganser and Guntram B{\"u}sche and Anne Letsch and Philippe Schafhausen and Gesine Bug and Br{\"u}mmendorf, {Tim H} and Rainer Haas and Lorenz Tr{\"u}mper and Katayoon Shirneshan and Detlef Haase",
year = "2017",
month = jun,
doi = "10.1007/s00277-017-2983-0",
language = "English",
volume = "96",
pages = "887--894",
journal = "ANN HEMATOL",
issn = "0939-5555",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial

AU - Braulke, Friederike

AU - Schulz, Xenia

AU - Germing, Ulrich

AU - Schuler, Esther

AU - Platzbecker, Uwe

AU - Nolte, Florian

AU - Hofmann, Wolf-Karsten

AU - Giagounidis, Aristoteles

AU - Götze, Katharina

AU - Lübbert, Michael

AU - Schlenk, Richard F

AU - Schanz, Julie

AU - Bacher, Ulrike

AU - Ganser, Arnold

AU - Büsche, Guntram

AU - Letsch, Anne

AU - Schafhausen, Philippe

AU - Bug, Gesine

AU - Brümmendorf, Tim H

AU - Haas, Rainer

AU - Trümper, Lorenz

AU - Shirneshan, Katayoon

AU - Haase, Detlef

PY - 2017/6

Y1 - 2017/6

N2 - Transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndrome, <5% bone marrow (BM) blasts and isolated 5q-deletion received lenalidomide within the German MDS study group phase-II clinical trial LE-MON-5 (EudraCT:2008-001866-10) of the University of Duesseldorf, Germany. Cytogenetic monitoring was performed by chromosome banding analyses (CBA) of BM cells and fluorescence in situ hybridization (FISH) analyses of peripheral blood (PB) mononuclear CD34+ cells using extended probe panels. Out of 144 patients screened for study enrollment, 24% failed to meet inclusion criteria due to cytogenetic findings. Eighty-seven patients were followed with a median observation time of 30 months. Cytogenetic response detected by FISH and CBA in 74 and 66% of patients, respectively, was predictive for hematologic response as well as of high prognostic relevance. After 2 years, AML rate was 8% for all patients. Karyotype evolution was detected in 21 (FISH)-34% (CBA) of patients associated with significantly shorter AML-free survival. Disease progression was first detectable on the cytogenetic level on average 5-6 months before recurrence of transfusion dependence. Our data show for the first time in a prospective setting that a cytogenetic monitoring from the PB helps to early identify treatment failure and progressive disease in lenalidomide-treated patients to improve clinical management.TRIAL REGISTRATION: EudraCT:2008-001866-10.

AB - Transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndrome, <5% bone marrow (BM) blasts and isolated 5q-deletion received lenalidomide within the German MDS study group phase-II clinical trial LE-MON-5 (EudraCT:2008-001866-10) of the University of Duesseldorf, Germany. Cytogenetic monitoring was performed by chromosome banding analyses (CBA) of BM cells and fluorescence in situ hybridization (FISH) analyses of peripheral blood (PB) mononuclear CD34+ cells using extended probe panels. Out of 144 patients screened for study enrollment, 24% failed to meet inclusion criteria due to cytogenetic findings. Eighty-seven patients were followed with a median observation time of 30 months. Cytogenetic response detected by FISH and CBA in 74 and 66% of patients, respectively, was predictive for hematologic response as well as of high prognostic relevance. After 2 years, AML rate was 8% for all patients. Karyotype evolution was detected in 21 (FISH)-34% (CBA) of patients associated with significantly shorter AML-free survival. Disease progression was first detectable on the cytogenetic level on average 5-6 months before recurrence of transfusion dependence. Our data show for the first time in a prospective setting that a cytogenetic monitoring from the PB helps to early identify treatment failure and progressive disease in lenalidomide-treated patients to improve clinical management.TRIAL REGISTRATION: EudraCT:2008-001866-10.

KW - Acute Disease

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Angiogenesis Inhibitors

KW - Antigens, CD34

KW - Chromosome Banding

KW - Chromosome Deletion

KW - Chromosomes, Human, Pair 5

KW - Disease-Free Survival

KW - Female

KW - Germany

KW - Humans

KW - In Situ Hybridization, Fluorescence

KW - Karyotyping

KW - Leukemia, Myeloid

KW - Leukocytes, Mononuclear

KW - Male

KW - Middle Aged

KW - Myelodysplastic Syndromes

KW - Prognosis

KW - Thalidomide

KW - Treatment Failure

KW - Clinical Trial, Phase II

KW - Journal Article

KW - Multicenter Study

U2 - 10.1007/s00277-017-2983-0

DO - 10.1007/s00277-017-2983-0

M3 - SCORING: Journal article

C2 - 28374162

VL - 96

SP - 887

EP - 894

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 6

ER -